Merus N.V. (MRUS) Prices 3.86M Share Offering at $28.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Merus Announces Pricing of Public Offering of Common Shares
November 4, 2021 9:02 PM EDTUTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we and our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the Offer Shares). Merus also granted the underwriters a 30-day option to purchase up to an additional 578,947 common shares (the Option Shares and together with the Offer Shares, the Shares). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and... More
